Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.
Gluz O, Nitz UA, Harbeck N, Ting E, Kates R, Herr A, Lindemann W, Jackisch C, Berdel WE, Kirchner H, Metzner B, Werner F, Schütt G, Frick M, Poremba C, Diallo-Danebrock R, Mohrmann S; West German Study Group.
Gluz O, et al. Among authors: diallo danebrock r.
Ann Oncol. 2008 May;19(5):861-70. doi: 10.1093/annonc/mdm551. Epub 2008 Jan 3.
Ann Oncol. 2008.
PMID: 18174609
Free article.
Clinical Trial.